Telmisartan is an angiotensin 2 receptor blocker indicated for treatment of hypertension to lower blood pressure. It is available as tablets for oral use. MedsAcross supplies Telmisartan for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Telmisartanis an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions
Source: US FDA prescribing information
Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Telmisartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT 1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is therefore independent of the pathways for angiotensin II synthesis. There is also an AT 2 receptor found in many tissues, but AT 2 is not known to be associated with cardiovascular homeostasis. Telmisartan has much greater affinity (>3,000 fold) for the AT 1 receptor than for the AT 2 receptor.
Source: US FDA prescribing information
• May be administered with or without food. Indication Starting Dose Dose Range Hypertenstion 40 mg once daily 40 to 80 mg once daily Hypertension Dosage must be individualized. The usual starting dose of telmisartan tablets is 40 mg once a day. Blood pressure response is dose-related over the range of 20 to 80 mg. Most of the antihypertensive effect is apparent within 2 weeks and maximal reduction is generally attained after 4 weeks. When additional blood pressure reduction beyond that achieved with 80 mg telmisartan is required, a diuretic may be added. No initial dosage adjustment is necessary for elderly patients or patients with renal impairment, including those on hemodialysis. Patients on dialysis may develop orthostatic hypotension, their blood pressure should be closely monitored. Telmisartan tablets may be administered with other antihypertensive agents.
Source: US FDA prescribing information
Telmisartan is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis or angioedema) to telmisartan or any other component of this product. Do not co-administer aliskiren with telmisartan in patients with diabetes. Known hypersensitivity (e.g., anaphylaxis or angioedema)to telmisartan or any other component of this product.
Source: US FDA prescribing information
Boxed warning (fetal toxicity): When pregnancy is detected, discontinue telmisartan as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. WARNING: FETAL TOXICITY s. Drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus Avoid fetal or neonatal exposure. Hypotension: Correct any volume or salt depletion before initiating therapy. Observe for signs and symptoms of hypotension. Monitor carefully in patients with impaired hepatic or renal function. Avoid concomitant use of an ACE inhibitor and angiotensin receptor blocker
Source: US FDA prescribing information
The following adverse reaction is described elsewhere in labeling: • Renal dysfunction upon use with ramipril Hypertension: The most common adverse events (≥1%) reported in hypertension trials are back pain, sinusitis, and diarrhea
Source: US FDA prescribing information
Aliskiren: Do not co-administer aliskiren with telmisartan in patients with diabetes. Avoid use of aliskiren with telmisartan in patients with renal impairment (GFR <60 ml/min). Digoxin: When telmisartan was co-administered with digoxin, median increases in digoxin peak plasma concentration (49%) and in trough concentration (20%) were observed. Therefore, monitor digoxin levels when initiating, adjusting, and discontinuing telmisartan for the purpose of keeping the digoxin level within the therapeutic range. Lithium: Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists including telmisartan. Therefore, monitor serum lithium levels during concomitant use.
Source: US FDA prescribing information
Storage Store at 20° to 25°C (68° to 77°F), excursions permitted to 15° to 30°C (59° to 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
3 presentations of Telmisartan, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Telmisartan 80 mg tabletOralGeneric name | — | US FDA | Available on request |
| Telmisartan 40 mg tabletOralGeneric name | — | US FDA | Available on request |
| Telmisartan 20 mg tabletOralGeneric name | — | US FDA | Available on request |
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Telmisartan in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 3 presentations of Telmisartan and sources them for licensed hospitals, importers and physicians against valid import documents.
Yes. The US FDA first approved Telmisartan on 10 November 1998, according to Drugs@FDA.
Yes. Telmisartan has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Telmisartan is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Telmisartan is classified under ATC code C09CA07 (Telmisartan).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.